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Abstract: 
Objectives: This study examined five year outcomes of patients prescribed risperidone 
long-acting injection (RLAI) or aripiprazole in a clinical setting, using treatment 
discontinuation as a measure of effectiveness. 
Method: Patients who received RLAI or aripiprazole in the 18 months following their 
respective UK launches were included. Two year outcome data has previously been 
reported for these cohorts; this study reported an additional three years of follow-up for 
each group. Data were collected from pharmacy records and by retrospective case note 
review. Patients were classified as continuers or discontinuers at five years, and reasons 
for treatment discontinuation noted.  
Results: The number of patients remaining on treatment at two years (and included in 
this study) was 28/84 and 27/92 for RLAI and aripiprazole respectively. Of the 55 
patients included, two treated with RLAI and three treated with aripiprazole were lost to 
follow-up. Therefore, five year outcome data were available for 50 patients (26 RLAI and 
24 aripiprazole). Fifteen patients from each group were continuers at five years. Of the 
30 continuers, four receiving RLAI and three receiving aripiprazole were co-prescribed 
other antipsychotics at study endpoint. Reasons for discontinuation of RLAI and 
aripiprazole respectively were a lack of effect (n=4; 4), adverse effects (n=3; 1), non-
compliance or patient choice (n=2; 4), and patient death (n=2; 0).  
Conclusions: There was no significant difference between the proportions of patients 
continuing RLAI or aripiprazole for five years. Continuation rates were relatively low (18% 
and 16% of the original RLAI and aripiprazole cohorts respectively), whilst co-
prescription of other antipsychotics at endpoint was relatively common. Lack of 
effectiveness was the most common reason for discontinuation of both compounds. 
These findings suggested that clinical effectiveness was somewhat disappointing 
although the long period of follow-up and number of patients previously treated with 
clozapine in the original cohorts were confounding factors. 
Keywords: antipsychotic agents/therapeutic use; risperidone, aripiprazole 
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Introduction: 
The antipsychotic treatments risperidone long acting injection (RLAI) and aripiprazole 
(tablet formulation) have been available in the UK since October 2002 and July 2004 
respectively. When launched, both represented novel approaches to the treatment of 
psychosis. RLAI was the first available long acting injectable preparation of an atypical 
antipsychotic, with the potential advantages of reduced covert non-adherence compared 
to oral medication (Barnes and Curson, 1994) and reduced propensity for extra-
pyramidal side effects compared with typical antipsychotics (Leucht et al., 1999). 
Aripiprazole had a novel pharmacology, (with partial agonist rather than antagonist 
properties at the dopamine D2 receptor) which suggested that it would be associated 
with a favourable adverse effect profile (Taylor, 2003) together with the potential 
associated benefits of improved adherence and outcome (Lambert and Naber, 2004). 
 
Data from randomised controlled trials (RCTs) have provided evidence for the efficacy of 
RLAI (Kane et al., 2003) and aripiprazole (Potkin et al., 2003) in the treatment of 
psychosis. However, RCTs typically assess treatment outcome over a short period of 
time, which may have limited applicability to the clinical management of a chronic illness 
such as schizophrenia. Furthermore, due to strict inclusion and exclusion criteria, 
participants may not be representative of patients routinely seen in practice. 
Consequently, naturalistic patient follow-up studies (e.g. Attard et al., 2014), and studies 
using pragmatic outcome measures (e.g. Lieberman et al., 2005) have been used to 
evaluate the effectiveness of a number of different antipsychotics in settings more 
relevant to clinical practice. Both RLAI and aripiprazole have been the focus of several 
such studies with periods of follow-up ranging from six months (Deslandes et al., 2008; 
Taylor et al., 2007) to three years (Taylor et al., 2009). Given the chronic and relapsing 
nature of schizophrenia and the burden of the disease, studies with longer periods of 
follow-up remain important to assess treatment outcome (Turner, 2004). 
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This study examined five year outcomes of patients prescribed RLAI or oral aripiprazole 
in a clinical setting, using treatment continuation as a measure of effectiveness in order 
to evaluate their longer term value. 
 
Methods: 
Design 
This was a retrospective, naturalistic follow-up study of patients with a diagnosis of 
schizophrenia or schizoaffetive disorder, prescribed RLAI or aripiprazole tablets in 
clinical practice in the two years following their respective UK introductions. Two year 
outcome data has previously been reported for these cohorts (Deslandes et al., 2009a 
and 2009b). This study reported an additional three years of follow-up for patients 
continuing either treatment at two years. The original study was reviewed by the South 
East Wales Research Ethics committee panel C (reference number 04/WSE03/25). 
 
Participants and outcome measures 
Out of the original cohorts of 176 patients (84 RLAI and 92 aripiprazole), those remaining 
on treatment at two years were identified. Data were collected from pharmacy records 
and by retrospective case note review during a six week period throughout February and 
March 2013. Patients were retrospectively categorized either as those remaining on 
treatment (at five years), classified as “continuers”, or individuals who had discontinued 
treatment and designated “discontinuers”. The reason for discontinuation was recorded 
for all patients who stopped treatment during the study period. Where the reason for 
discontinuation was recorded as “patient refusal”, subjects were either disengaging from 
mental health services, or exhibited a lack of insight resulting in them refusing treatment. 
In some cases, adverse effects were the primary reason for a patient refusing (and 
discontinuing) treatment, such individuals were categorised as discontinuing due to 
adverse effects. The duration of treatment and the antipsychotic to which patients were 
switched following discontinuation were also noted. Patients’ drug histories were 
reviewed in order to determine whether or not they had previously been treated with 
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clozapine. This information was used to provide an indication that their condition had 
previously been unresponsive to treatment. Due to a possible association between RLAI 
discontinuation in patients who had previously experienced two treatment failures with 
other antipsychotics (Deslandes et al., 2009a), this information was also recorded. For 
patients prescribed aripiprazole, inpatient or outpatient status at initiation was recorded. 
The maintenance dose upon treatment discontinuation (or at five years for continuers) 
and the details of any co-prescribed antipsychotics were recorded for all patients. 
 
Analysis 
Outcomes of patient subgroups based upon previous clozapine treatment, two or more 
previous treatment failures and inpatient versus outpatient status at initiation were 
compared. Continuous variables were compared using unpaired Student t-test. Chi-
squared test or Fisher’s Exact test were used to compare categorical data. All statistical 
analyses were conducted using InStat (Instant Biostatistics) version 3.0 (GraphPad 
Software, USA).\ 
 
 
Results: 
The number of patients remaining on treatment at two years (and therefore included in 
this study) was 28/84 and 27/92 of the original RLAI and aripiprazole cohorts 
respectively. Out of the 55 patients included, two treated with RLAI and three treated with 
aripiprazole were lost to follow-up. Therefore, five year outcome data were available for 
50 patients (26 RLAI and 24 aripiprazole). Six patients receiving RLAI and seven 
receiving aripiprazole had previously been treated with clozapine. Patient demographics, 
reasons for treatment initiation and mean dose at study endpoint are shown in table 1. 
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Table 1.  Patient demographics and reasons for treatment initiation 
 
 RLAI Aripiprazole 
 
Continuers 
(n=15) 
Discontinuers 
(n=11) 
Continuers 
(n=15) 
Discontinuers 
(n=9) 
Age at initiation (years)     
Mean ± sd 37.5 ± 9.2 38.5 ± 17.3 40.5 ± 12.8 44.7 ± 12.7 
Range 20–53 19–70 19–71 33–71 
     Gender n (%)     
Male 10 (67) 8 (73) 7 (47) 3 (33) 
Female 5 (33) 3 (27) 8 (53) 6 (67) 
     Ethnicity n (%)     
Caucasian 15 (100) 6 (55) 11 (73) 9 (100) 
Non-caucasian 0 (0) 5 (45) 4 (27) 0 (0) 
     Previous clozapine n (%) 4 (27) 2 (18) 2 (13) 5 (56) 
     Two or more previous 
antipsychotic trials n (%) 4 (27) 2 (18) 11 (73) 9 (100) 
     
Status on initiation n (%):     
Inpatient – – 2 (13) 4 (44) 
Outpatient – – 13 (87) 5 (56) 
     Reason for initiation n (%)     
Previous non-compliance 14 (93) 11 (100) 0 (0) 2 (22) 
Previous poor response 1 (7) 0 (0) 5 (33) 4 (44) 
Previous adverse effects 0 (0) 0 (0) 9 (60) 3 (33) 
Patient choice 0 (0) 0 (0) 1 (7) 0 (0) 
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Patients continuing treatment: 
The proportion of patients remaining on treatment over time is shown in figures 1 and 2. 
Figure 1 shows the proportion of the original RLAI and aripiprazole cohorts on treatment 
from time 0 to five years excluding those lost to follow-up in the current study (n=82 and 
n=89 for RLAI and aripiprazole respectively). Figure 2 shows the proportion of continuers 
at year two (n=50) remaining on treatment from year two up to the study endpoint at year 
five according to whether they had previously been treated with clozapine (C) or had not 
previously been treated with clozapine (NC). Fifteen patients from each cohort were 
continuers at five years; there was no significant difference between the proportions 
continuing RLAI or aripiprazole (p=0.73 Chi-square test). Previous clozapine treatment or 
a history of two or more previous treatment failures did not predict outcome with either 
RLAI (p=1.0 Fisher’s Exact test) or aripiprazole (p=0.06 and 0.26 respectively, Fisher’s 
Exact test). Similarly inpatient or outpatient status at initiation did not predict aripiprazole 
outcome (p=0.15 Fisher’s Exact test). Mean doses ± sd at five years were 47.5mg ± 
15.8mg and 16.8mg ± 8.4mg for RLAI and aripiprazole respectively. Four of the RLAI 
continuers (26%) and one of the aripiprazole continuers (7%) were co-prescribed other 
antipsychotics at five years. Risperidone (n=3) and amisulpride (n=1) were the co-
prescribed antipsychotics in the RLAI cohort, and chlorpromazine was the co-prescribed 
antipsychotic in the aripiprazole cohort. 
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Figure 1. Proportion of original patient cohorts remaining on treatment over time 
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Figure 2.  Proportion of patients remaining on treatment from 2–5 years 
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Patients discontinuing treatment: 
Reasons for treatment discontinuation, dose at discontinuation and the antipsychotic to 
which patients were switched are shown in table 2. Patients were categorized by 
treatment and according to whether or not they had previously received clozapine. Doses 
for the RLAI group represent mean fortnightly dose. Poor response was the most 
common reason for discontinuation in both groups. 
 
 
Table 2 Reasons for discontinuation 
 
 RLAI Aripiprazole 
 
Clozapine 
(n=2) 
Non-clozapine 
(n=9) 
Clozapine 
(n=5) 
Non-clozapine 
(n=4) 
Dose at discontinuation (mg)     
Mean ± sd 50 ± 0 38.4 ± 17.5 24.0 ± 8.2 15 ± 10 
Range 50 25–75 15–30 10–30 
     Reason for discontinuation. (n)      
Poor response 2  2  3 1 
Non-compliance 0 1  1 2 
Adverse effects 0 3  1 0 
Patient choice 0 1  0 1 
Patient death 0 2  0 0 
     Switched to. (n)      
Oral atypical (not clozapine) 0 7 2 2 
Oral typical 0 0 2 0 
Long acting atypical 0 0 1 0 
Clozapine 2 0 0 0 
No treatment 0 2 0 2 
 
 
 
Discussion: 
This study assessed clinical outcomes of patients treated with two novel antipsychotic 
preparations over an extended period of time. Overall continuation rates from time 0 to 
five years for the original cohorts of 176 patients were relatively low (18% and 16% of 
RLAI and aripiprazole treated patients respectively). However, of the 50 patients 
remaining on treatment at two years (the focus of the present study), 60% completed an 
additional three years of treatment, and were therefore continuers at five years. There 
was no significant difference between the proportions of patients continuing RLAI or 
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aripiprazole at five years. Reasons for discontinuation were comparable, with lack of 
effectiveness being the most common reason for cessation of both compounds. Co-
prescription of other antipsychotics was relatively common (17% of all continuers at five 
years).  
 
This study was not specifically designed to compare outcomes between patients treated 
with either RLAI or oral aripiprazole or between subgroups of patients treated with each 
drug. Indeed, data from the two cohorts were collected over different time periods and 
the demographics of the two groups (particularly reasons for treatment initiation) were 
different. However, there was no significant difference in the proportion of patients 
continuing either drug at five years, although it must also be noted that there may not 
have been sufficient power to detect such a difference. This is consistent with the 
findings of a two year, open label study examining outcomes with these antipsychotics 
(Macfadded et al., 2010). It has been suggested that long-acting injectable formulations 
of antipsychotics may be more effective than oral formulations of the same drug (Tihonen 
et al., 2006). This may be due to a reduction in overt non-compliance associated with the 
long-acting injections, with subsequent benefits in treatment outcome (Novick et al., 
2010). Whilst overall levels of discontinuation in our study were similar, it is perhaps 
interesting to note that the proportion of patients discontinuing due to non-compliance 
(9% and 33% for RLAI and aripiprazole respectively) favoured the long-acting injectable 
preparation in this regard. Conversely, the proportion of patients discontinuing due to 
adverse effects (27% and 11% for RLAI and aripiprazole respectively) suggested that the 
hypothesized improved tolerability profile of aripiprazole (Taylor, 2003) has been realised 
in clinical practice. It should be noted that in addition to the limitations mentioned above, 
the number of patients discontinuing due to these reasons was small (n=8) making it 
difficult to draw definitive conclusions from these findings.  
 
The proportion of patients discontinuing treatment, and the level of antipsychotic co-
prescribing at five years suggested that the clinical effectiveness of both RLAI and 
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aripiprazole was somewhat disappointing. However, the long period of follow-up and 
large number of patients previously treated with clozapine in the original cohorts were 
confounding factors. Results with RLAI at three years (29% continuation) were consistent 
with the findings of another naturalistic study, which reported a 33% continuation rate at 
the same time point (Taylor et al., 2009). An open label study comparing RLAI and 
aripiprazole over two years reported continuation rates of 69% and 61% respectively, 
with 7.9% of RLAI and 11% of aripiprazole patients co-prescribed an antipsychotic 
(Macfadden et al, 2010). The continuation rate was somewhat higher than that seen in 
our study at two years, which may reflect the differing study designs. At five years, 26% 
of RLAI and 7% of aripiprazole continuers in our study were co-prescribed an 
antipsychotic. The rate of co-prescribing with aripiprazole was comparable to that seen 
by Macfadden et al., (2010). The rate for RLAI was considerably higher, although 
somewhat lower than the 46% reported by Aggarwal et al (2012) in a study of 
antipsychotic long-acting injection use in clinical practice in the USA. The five year 
follow-up period in the present study may explain this difference, as patients requiring 
supplementation (and therefore presumably showing a sub-optimal response to 
treatment) may have discontinued prior to study end-point. Oral risperidone was the most 
commonly co-prescribed medicine in the RLAI group. This perhaps suggested that 
patients showed some response but required a higher plasma level of the drug than that 
provided by the injectable formulation alone in order to achieve a maximal response.  
 
Whilst discontinuation over the whole five year period was high, continuation of treatment 
at year two appeared to be a relatively good predictor of continuation at year five for both 
of the treatments studied. Findings from the RLAI cohort showed that previous poor 
response to antipsychotic treatment was associated with early discontinuation 
(Deslandes et al., 2009). It could be argued that excluding patients who discontinued 
early (< 1 year) in treatment, and assessing response over the subsequent four years 
would have shown a more positive outcome. This is consistent with the view that in 
clinical practice newly launched antipsychotics are often prescribed for hard to treat 
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patients who have failed to respond to other drugs, thereby increasing the likelihood of 
treatment failure (Young and Taylor 2006). However, it should also be noted that longer 
term studies indicate that patients with schizophrenia tend to stabilise in any event after 
approximately five years through the natural alleviations of the disease and with 
progressing age and maturity (Harrison et al., 2001). Despite all of the patients who 
discontinued RLAI being initiated due to poor compliance, the agent that they were 
switched to following discontinuation was an oral (non-clozapine) atypical antipsychotic. 
This would appear somewhat illogical if previous poor compliance had been a reason for 
initiation of long-acting injectable treatment. Subsequent outcomes for this subgroup 
were not evaluated, but would be of potential benefit in order to explore the effectiveness 
of this treatment approach. 
 
This study provided evidence for the effectiveness of RLAI and aripiprazole in a real-
world clinical setting over an extended time period. Continuation rates with both 
compounds over the whole five year period were somewhat disappointing which may 
have been due in part to the long period of follow up and number of patients previously 
treated with clozapine. However, a relatively large proportion of the two cohorts included 
in the present study remained on treatment from year two to year five, which highlighted 
the importance of appropriate prescribing to minimize early discontinuation and achieve 
good outcomes in a clinical setting. 
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